AVE 20.0% 0.3¢ avecho biotechnology limited

Ann: Elixia range of Personal Care Products - Upd, page-3

  1. 34,916 Posts.
    lightbulb Created with Sketch. 480
    re: Ann: Elixia range of Personal Care Produc... Phosphagenics on track to reach $1 million target for
    personal care products
    ? New Australian stockists confirmed
    ? 20,000 plus units sold since April 2011
    ? US strategic push in second half of 2011
    28 June 2011, Melbourne, Australia: Melbourne biotechnology company
    Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) is on track to reach its million
    dollar sales revenue target by the end of July for its Elixia? range of Personal Care
    products.
    The sales result comes as the company adds two further high profile stockists for
    Elixia? products: Terry White Group and Symbion Pharmacy Services to its growing
    list of retail outlets in Australia.
    Phosphagenics CEO, Dr Esra Ogru, said more than 20,000 units of Elixia? ? all
    containing the company?s patented TPM? transdermal delivery technology ? had
    been sold since the company launched three new cosmetic lines in April this year.
    ?These sales results have exceeded our expectations and are further endorsement of
    the company?s versatile platform technology,? she said.
    The products were launched on the TVSN home shopping channel and online,
    before being made available in flagship Myer Retail Group stores in late May, and
    selected Pulse Pharmacies in June.
    Dr Ogru said while the entire range had experienced outstanding sales, the
    BodyShaper Cellulite Contour Cr?me? in particular had far exceeded initial sales
    forecasts.
    She said manufacturers had been forced to double initial production capacity and
    almost ten thousand units of this product alone have been sold.
    Dr Ogru indicated the company was also in late stage discussions with a large Asian
    based distributor and had just finalized negotiations with a specialist distributor into
    spa, salons and beauty outlets in Hong Kong and Macau.
    ?Asia is also a major focus for brand growth and we are continuing negotiations with
    key distributors in this region,? Dr Ogru said.
    ?Moreover, our strategic push into the United States in the second half of this year
    will mean our Elixia? products are stocked on shelves in US department stores.
    Page 2 of 2
    Elixia? is an Australian owned and developed brand which includes anti-ageing
    skincare formulas, specially developed to penetrate and target fine lines and
    wrinkles. Its active ingredients include SNAP-8, Carnosine and CoQ10. TPM? is a
    patented world first delivery technology which enables superior penetration of these
    active ingredients into the skin.
    The BodyShaper Cellulite Contour Cr?me? uses this technology to deliver fatreducing
    molecules into the skin. The product includes the proprietary anti-fat
    peptide AOP9604 (which has been licensed to Phosphagenics) and two other
    lipolytic molecules, caffeine and forskolin.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.001(20.0%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $408 154.2K

Buyers (Bids)

No. Vol. Price($)
61 90794613 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 54998583 13
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.